Peripheral/Endo

Microbot Medical® Welcomes Updated Occupational Protection Guidelines from Leading Medical Societies, Strengthening Commercial Position of LIBERTY®

Peripheral/Endo by 0 comments

Members of the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Represent the Largest Addressable User Market for the LIBERTY System At least Nine Medical Societies Endorse Updated Guidelines to Lower Radiation Exposure and Improve Ergonomic Issues Impacting Health Practitioners HINGHAM, Mass., April 22, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, today highlighted that the Society of Interventional Radiology (SIR) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE), recently released updated joint guidelines on occupational protection in interventional radiology. The revised guideline provides important safety guidance to physicians, radiographers, nurses, medical physics experts, and all other staff involved in interventional radiology procedures. The guidelines, which were published in CardioVascular and Interventional Radiology (CVIR), cover updated clinical evidence, new exposure sources and address musculoskeletal risks for interventional radiology staff and, for the first time, include a section on radiation protection during pregnancy for female practitioners. “Part of our mission for the LIBERTY System is to enable physicians to continue improving and saving patients’ lives while protecting their own. LIBERTY’s design aims to reduce radiation exposure and physical strain for physicians and related medical staff, positioning the LIBERTY System as a potential solution to address both the health, and the staffing challenges in interventional care,” commented Harel Gadot, Chairman, CEO & President. “It is very encouraging to see increased emphasis on protecting healthcare providers in the interventional space coming from leading medical societies, such as the American Medical Association (AMA), one of the largest medical associations in the U.S., along with SIR and CIRSE.” Prolonged exposure to radiation may have significant long-term health risks, including cancer, cardiovascular disease, reproductive health effects, and cataracts. These risks have also been cited as contributing to the staffing shortage in the endovascular space, especially in interventional radiology, which currently ranks number two among specialties with highest physician shortages. The burden disproportionately affects women, who often cite radiation exposure and the physical demands of wearing lead aprons as barriers to entering or advancing in the field. The LIBERTY System’s remote operation capabilities enable physicians to work away from the radiation source and in a seated position, potentially lowering musculoskeletal strain while improving workflow efficiency. Along with SIR and CIRSE, occupational protection initiatives are being endorsed by the Society of NeuroInterventional Surgery (SNIS), the Society of Vascular and Interventional Neurology (SVIN), the Society for Cardiovascular Angiography and Interventions (SCAI), American College of Cardiology (ACC), the Alliance for Cardiovascular Professionals (ACVP), the American Society of Echocardiography (ASE), the Heart Rhythm Society (HRS), and Society for Vascular Surgery (SVS). Additionally, in late 2025, the American Medical Association (AMA) adopted a new policy to strengthen protections for healthcare professionals and trainees who may face occupational radiation exposure. The policy emphasizes the importance of continued research into the health effects of cumulative exposure to ionizing radiation, as well as education and training to minimize occupational risk to physicians and patients. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care. Learn more at www.microbotmedical.com and connect on LinkedIn and X. Safe Harbor Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Contacts: IR@microbotmedical.comMedia@microbotmedical.com

Continue Reading →

Efemoral Medical Reports Exceptional Long-Term EFEMORAL I Results Highlighting Durability and Differentiated Performance in Femoropopliteal Disease

Peripheral/Endo by 0 comments

Novel bioresorbable scaffold demonstrates primary patency rate of 97% at 3 years, indicative of long-term efficacy Achieved 1% post-procedural residual stenosis rate — lowest rate ever reported in a clinical trial of femoropopliteal intervention LOS ALTOS, Calif., April 21, 2026 /PRNewswire/ — Efemoral Medical announced today that at the Charing Cross Symposium in London, […]

Continue Reading →

Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment

Peripheral/Endo by 0 comments

Data demonstrates strong and higher secondary patency compared to conventional arteriovenous grafts (AVG) to meaningfully transform vascular access79% secondary patency at 12 months in complex patient populations supported by low reintervention burden (1.3 patency‑related reintervention rate per patient year) and a 3% clinically relevant access related infection rate CE mark approval enables Xeltis to commercialize aXess™ in Europe EINDHOVEN, The Netherlands, April 21, 2026 (GLOBE NEWSWIRE) — Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announced new 12-month clinical data from the aXess multi-center EU pivotal trial, which enrolled 120 patients in 22 clinical trial sites from 9 European countries, demonstrating the transformative potential of aXess™ in hemodialysis treatment. The 12-month pivotal data demonstrate strong and higher secondary patency of aXess™ compared to conventional arteriovenous grafts (AVG), requiring fewer interventions, lower re-intervention rate compared to standard of care and high infection resistance compared to grafts. The aXess pivotal study enrolled a real-world patient population, in which most (69%) of the patients had previously used a central venous catheter (CVC) and had a failed fistula. Findings demonstrated strong durability outcomes, including 79% secondary patency and a very low patency‑related reintervention rate of 1.3 per patient year, alongside a substantial reduction in infection burden. Compared with alternative access options using published benchmark data, patency‑related reinterventions were 60% lower than AVGs and 30% lower than arteriovenous fistulas (AVF), meaning fewer access procedures for patients. At one year, the access‑related infection rate was 3%, versus 22% for CVCs and 9% for AVGs. These findings build on earlier evidence from the six-month EU pivotal trial results which demonstrated significantly improved clinical outcomes compared with ePTFE AVGs, benchmarked against established objective performance criteria, and reconfirm earlier findings observed across previous studies. Importantly, these outcomes are further reinforced by the durability demonstrated across Xeltis’ broader clinical experience including excellent 24-month first-in-human outcomes from a 20-patient European study, as well as long-term clinical cases with follow-up now exceeding four years, providing compelling evidence of longevity and sustained function over time. Taken together with the newly available 12-month pivotal trial data, this comprehensive body of evidence underscores both the clinical benefit and long-term durability of the technology. CE mark approval was obtained in record time, enabling Xeltis to commercialize aXess™ in Europe. Eliane Schutte, Chief Executive Officer, Xeltis, said: “These are tremendous results and represent the first large-scale clinical dataset of its kind generated in Europe. The data demonstrate that aXess™ is safe and easy to implant, and by 12 months transforms into a tissue-like, pulsating conduit. With this level of clinical evidence, we can now move forward with the commercialization of aXess™ and begin delivering it to patients in real-world clinical practice. Patients deserve better options, and this technology has the potential to transform outcomes and save lives.” Dr. Augusto Ministro, Professor of Vascular Surgery at ULS Santa Maria, Portugal, commented: “The combination of a reduced intervention burden, strong infection resistance, early cannulation capability, and a short time to hemostasis represents a significant advance for patients and clinicians alike. These attributes address many of the persistent challenges associated with conventional vascular access, making aXess™ a highly compelling option for improving durability, usability, and overall patient outcomes.” Dr. An De Vriese, Head of the Dept of Internal Medicine and Division of Nephrology and Infectious Disease at AZ Sint-Jan Brugge, Belgium, and co-Principal Investigator of the study, commented: “The 2 pillars of aXess™ are reduced interventions and low intervention rates. The short time to hemostasis is very important for improving the quality of life of the patient.” Dr. Peter Schneider, Professor of Surgery in the Division of Vascular & Endovascular Surgery at University of California, San Francisco, US, added: “Having endothelium along the entire lumen of what started out as a prosthetic graft is a holy grail in our field that many have tried to achieve. It looks like now we finally have it.” Built on Nobel Prize-winning science, aXess™ leverages Restorex™ breakthrough polymer technology, transforming into the patient’s own tissue, forming a living vessel for sustained vascular access and reducing intervention burden and catheter dependency. The Xeltis team presented these data at The 48th Charing Cross Symposium, London, UK, from 21-23 April 2026. Contacts XeltisEliane Schutte, CEOAlexander Goemans, CFOinfo@xeltis.com Optimum Strategic CommunicationsNick Bastin, Eleanor Cooper, Aoife Minihan +44 (0) 208 078 4357xeltis@optimumcomms.com   About XeltisXeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. Xeltis seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company’s proprietary Restorex™ platform utilizes an advanced polymer implant which regenerates the patient’s own tissue before gradually being absorbed and leaving new, living and long-lasting vessels in place. Xeltis’ most advanced product currently under commercial development is aXessTM, an implantable blood vessel for hemodialysis vascular access. Xeltis’ groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases. Xeltis is based in The Netherlands and the USA. Its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, Ysios Capital, Grand Pharma Group, the European Innovation Council and Invest-NL, in addition to other public and private investors. Visit the Xeltis website for more details: https://xeltis.com/

Continue Reading →

Catheter Precision Secures U.S. Patent Allowance on Foundational Surgical Technology, Establishing Powerful IP and Accelerating Scalable Growth Strategy

Peripheral/Endo by 0 comments

USPTO Validates Catheter Precision’s LockeT Technology with Key Patent Allowance, Reinforcing Competitive Dominance, Long-Term Value Creation and Strengthening Barriers to EntryFORT MILL, S.C., April 21, 2026 (GLOBE NEWSWIRE) — Catheter Precision, Inc. (NYSE American: VTAK) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for key claims covering its proprietary surgical vessel closing pressure device, marking a significant milestone in the Company’s intellectual property strategy. Following a rigorous examination process, the USPTO confirmed the novelty and patentability of VTAK’s technology over existing prior art. The allowed claims provide protection across both the core device architecture and its method of use, creating a comprehensive and defensible intellectual property position around a foundational component of the Company’s platform. The patented system incorporates a differentiated design enabling precise control of suture tension and pressure application after vascular procedures, supporting effective hemostasis. By securing protection over both structural and functional elements of the technology, VTAK is establishing meaningful barriers to entry and reinforcing its competitive position in complex procedural markets. “This milestone further underscores Catheter Precision’s commitment to innovation and strengthens its foundation for driving significant long-term shareholder value,” said David A. Jenkins, Chief Executive Officer of Catheter Precision. He continued, “VTAK continues to execute on its strategy of developing differentiated, high-impact medical technologies supported by strong intellectual property protection, positioning the Company for sustained growth and long-term value creation.” This milestone represents a critical step in building a scalable, IP-driven medical technology platform. The Company believes its expanding patent portfolio will play a key role in supporting long-term commercialization, product development, and potential strategic opportunities. About LockeT Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA and has received CE Mark approval. About Catheter Precision Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “anticipate,” “potential,” “will,” “may,” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, expectations regarding potential strategic transactions, valuation outcomes, market opportunities, and the Company’s growth strategy. These statements involve risks and uncertainties that could cause actual results to differ materially. For a discussion of these risks, please refer to the Company’s filings with the SEC, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements. CONTACTS: Investor Relations973-691-2000IR@catheterprecision.com

Continue Reading →

INVERA MEDICAL REPORTS 12-MONTH RESULTS FROM PILOT TRIAL OF INVERA INFUSION DEVICE SHOWING VEIN CLOSURE IN 90% OF PATIENTS, STATISTICALLY SIGNIFICANT QUALITY OF LIFE IMPROVEMENTS, AND EXCELLENT SAFETY

Peripheral/Endo by 0 comments

Novel Non-Thermal Procedure for Chronic Venous Disease Designed to Effectively Eliminate Need for Painful Injections Required for Thermal Ablation GALWAY, Ireland, April 21, 2026 /PRNewswire/ — InVera Medical, a medical device company focused on advancing minimally-invasive technologies…

Continue Reading →

Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit™, as it moves to commercialization

Peripheral/Endo by 0 comments

CE mark awarded for aXess™ at record speed, underpinned by strong EU pivotal trial data Xeltis advances ahead of schedule to commercializationaXess™ reduces the need for vascular access interventions enabling more streamlined kidney care delivery EINDHOVEN, The Netherlands, April 21, 2026 (GLOBE NEWSWIRE) — Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, today announces that it has received the CE mark for aXess™, its restorative vascular access conduit for hemodialysis treatment, marking a significant regulatory milestone and the Company’s transition from a clinical-stage to a commercial-stage organization. The CE mark was granted following evaluation of all data including Xeltis’ European clinical pivotal trial results and was achieved in just 84 working days from submission, well ahead of schedule, reflecting the strength and completeness of the clinical evidence package. Built on Nobel Prize-winning science, aXess™ leverages Restorex™ materials, which triggers the body’s natural healing response to transform into the patient’s own tissue to form a living vessel for reliable vascular access. aXess™ is designed to reduce long-term catheter dependence and access issues – helping shift the hemodialysis journey for patients with end-stage kidney disease from repeated interventions toward more seamless care delivery and improved quality of life. Achieving CE mark approval represents a pivotal commercial inflection point for Xeltis, signaling the transition from clinical validation to market entry. The successful and timely completion of the CE marking process serves as a clear signal to clinicians, investors and strategic partners of the product’s readiness for real-world use. With CE marking in place, Xeltis can commercialize across European markets, enabling clinicians to confidently deploy aXess™ and allowing patients to benefit from an innovation that meets high standards of safety, performance and clinical evidence. Eliane Schutte, Chief Executive Officer of Xeltis, commented: “Receiving CE mark approval for aXess™ is a defining moment for Xeltis and a strong validation of our revolutionary restorative technology platform and the outstanding dedication of the entire Xeltis team. For patients undergoing hemodialysis, this milestone means we can offer a more reliable, long-lasting access option that can improve quality of life while reducing the burden of ongoing procedures. Achieving CE mark in just 84 working days underscores the strength of our clinical data and marks our transition from a clinical-stage company to a commercial organization.” Steve Phillips, Chief Strategy Officer of DaVita, said: “At DaVita, we’re committed to advancing technologies that meaningfully improve outcomes and elevate the care experience for people living with kidney disease. This milestone for Xeltis represents meaningful progress toward better clinical results and a more patient centered care experience.” Fred Colen, Chairman of the Board of Xeltis, added: “The Xeltis Board of Directors is very pleased with the performance of the Xeltis team under the leadership of CEO Eliane Schutte, to deliver on the promise of the exceptional Xeltis Technology Platform, to obtain the European CE Mark approval in record time, under the stringent European MDR regulations. Approval to start commercialization for its first application, access for dialysis patients addressing key limitations of existing treatment options in clinical use, is further testament to the promise of this technology.” Ferdinando Lamagna, Spokesperson at The British Standards Institution said: “At BSI, it is a pleasure to support MedTech organizations that bring meaningful innovation to the sector and ultimately benefit patients. Xeltis demonstrated a high level of preparation and a collaborative approach throughout the conformity assessment process, which progressed in an efficient and well-structured manner, with effective coordination between the parties. As a result, certification of this Class III implantable device was achieved within a notably short timeframe, taking into account the scope and complexity of the assessment, including a full Clinical Evaluation Consultation Procedure per MDR Article 54. We congratulate the Xeltis team on this important achievement and look forward to continuing our collaboration to support innovation in patient care.” The Xeltis team will be presenting its 12-month data at The 48th Charing Cross Symposium, London, UK, from 21-23 April 2026. Contacts XeltisEliane Schutte, CEOAlexander Goemans, CFOinfo@xeltis.com Optimum Strategic CommunicationsNick Bastin, Eleanor Cooper, Aoife Minihan +44 (0) 208 078 4357xeltis@optimumcomms.com   About XeltisXeltis is a medtech company developing transformative implants that enable the natural creation of living and long-lasting vessels. Xeltis seeks to address the limitations of currently available options for the millions of people requiring hemodialysis access grafts or cardiovascular replacements every year. The Company’s proprietary Restorex™ platform utilizes an advanced polymer implant which regenerates the patient’s own tissue before gradually being absorbed and leaving new, living and long-lasting vessels in place. Xeltis’ most advanced product currently under commercial development is aXess™, an implantable blood vessel for hemodialysis vascular access. Xeltis’ groundbreaking technology has high potential to be applied to other major vascular and cardiovascular diseases. Xeltis is based in The Netherlands and the USA. Its investors include DaVita Venture Group, EQT Life Sciences, Kurma Partners, VI Partners, Ysios Capital, Grand Pharma Group, the European Innovation Council and Invest-NL, in addition to other public and private investors. Visit the Xeltis website for more details: https://xeltis.com/

Continue Reading →

Reflow Medical Announces 12-Month Results from DEEPER REVEAL Trial: Sustained Outcomes with the Spur® Stent System in CLTI

Peripheral/Endo by 0 comments

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announces that 12-month results from the DEEPER REVEAL clinical trial (NCT05358353) were presented for the first time today at the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting in Toronto, Canada. […]

Continue Reading →

Microbot Medical® Commences Full Market Release (FMR) of the LIBERTY® Endovascular Robotic System in the U.S. at the Society of Interventional Radiology (SIR) Annual Scientific Meeting

Peripheral/Endo Radiology by 0 comments

Successful Execution of the Limited Market Release (LMR) Includes Adoption by Globally Recognized Healthcare Systems in the U.S. Market and Demonstrates Broad Market Scalability in Key Endovascular ProceduresHINGHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) — Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the innovative LIBERTY® Endovascular Robotic System, announced today that it has successfully executed its limited market release (LMR) and will commence its full market release (FMR) in the U.S. as planned. To date, LIBERTY has been adopted by multiple healthcare systems with dozens of hospitals in their networks, including globally recognized hospitals such as Emory Healthcare and Tampa General Hospital. Microbot considers this achievement a reflection of the highly effective execution of the LIBERTY System’s LMR and positions the Company to commence the FMR of the LIBERTY System as originally planned, at the Society of Interventional Radiology (SIR) Annual Scientific Meeting, being held in Toronto, ON, Canada, from April 11-15. The LIBERTY system is creating an entirely new category as the only FDA-cleared, single-use, remotely operated robotic system. It has been successfully used commercially across a variety of procedures, including Prostate Artery Embolization (PAE), Uterine Fibroid Embolization (UFE), Genicular Artery Embolization (GAE), Y90 mapping, Y90 deliveries, and peripheral arterial interventions. Physicians have highlighted LIBERTY’s precision, short learning curve, fast setup, the ability to use their preferred wires and catheters, as well as the potential to improve efficiency by reducing procedure time and number of instruments used to perform such procedures. In preparation for the FMR, the Company has further enhanced its commercial team core capabilities by adding salespeople in key locations and broadening its sales footprint from four to eight sales territories, with a goal of having 12 territories across the U.S. by the end of 2026. “We successfully achieved our goals for the limited market release of the LIBERTY System, including its adoption by leading hospitals across multiple peripheral procedures, giving us the momentum to commence, as planned, the full market release at the SIR conference,” commented Harel Gadot, Chairman, President & CEO. “It’s exciting to see the level of enthusiasm among our existing customers, first when they initially use LIBERTY, utilizing it across multiple procedures, and then as they expand it to other hospital sites within their network. The variety of case types shows the system’s flexibility, and its ease of use is generating high customer satisfaction. I also believe the level of customer adoption during the limited market release in such a short time further demonstrates a shorter sales cycle compared to traditional surgical robots, which is another key differentiator and one we believe will lead to accelerated adoption.” SIR represents over 8,000 practicing interventional radiology physicians, trainees, medical students, scientists, and clinical associates. This will be the first opportunity for the Company to showcase the LIBERTY system at the conference, which features its primary addressable U.S. target market. SIR, along with the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) have recently adopted new guidelines, which were published in CardioVascular and Interventional Radiology (CVIR), and endorsed by at least eight other medical societies. These guidelines cover updated evidence, address new exposure sources such as CT-guided procedures and radioembolization, and radiation protection during pregnancy for female practitioners, as well as addresses musculoskeletal risks for interventional radiology staff. This follows a recent American Medical Association (AMA) policy adopted late last year to strengthen protections for health care professionals from occupational exposure to ionizing radiation. “This year’s SIR conference is a pivotal moment for Microbot Medical, and the timing of the conference represents an optimal opportunity for our team to leverage the market feedback to commence the full market release of the LIBERTY System,” added Mr. Gadot. “Our targeted end users will be in attendance, and we plan to engage with them directly, enhancing our opportunities over the coming months as we broaden our presence in existing territories and expand into new ones.” The Company plans to meet with physicians and other stakeholders, to showcase the LIBERTY system at booth #423, and to further educate physicians on the system’s full capabilities to accelerate market adoption in the U.S. LIBERTY is the only FDA cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed for precise vascular navigation while aiming to reduce radiation exposure and physical strain, addressing key clinical and operational challenges faced by interventional radiology teams. About Microbot Medical Microbot Medical Inc. (NASDAQ: MBOT) is a commercial stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Microbot’s LIBERTY® Endovascular Robotic System is the world’s first FDA cleared single-use, remotely operated robotic solution designed for precision, efficiency and safety. Backed by a strong intellectual property portfolio and a commitment to innovation, Microbot is driving the future of endovascular care. Learn more at www.microbotmedical.com and connect on LinkedIn and X. Safe Harbor Statements to future financial and/or operating results, future adoption of products, future growth in research, technology, clinical development, commercialization and potential opportunities for Microbot Medical Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Any statements that are not historical fact (including, but not limited to statements that contain words such as “contemplates,” “continues,” “could,” “forecasts,” “intends,” “may,” “might,” “possible,” “potential,” “predicts,” “projects,” “should,” “would,” “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) should also be considered to be forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements involve risks and uncertainties, including, without limitation, market conditions, risks inherent in the commercialization of the LIBERTY® Endovascular Robotic System, and in the development of future versions of or applications for the system, uncertainty in the results of regulatory pathways and regulatory approvals, uncertainty resulting from political, social and geopolitical conditions, particularly any changes in personnel or processes or procedures at the FDA and announcements of tariffs on imports into the U.S., disruptions resulting from new and ongoing hostilities between Israel and the Palestinians, Iran and other neighboring countries, and maintenance of intellectual property rights. Additional information on risks facing Microbot Medical® can be found under the heading “Risk Factors” in Microbot Medical’s periodic reports filed with the Securities and Exchange Commission (SEC), which are available on the SEC’s web site at www.sec.gov. Microbot Medical® disclaims any intent or obligation to update these forward-looking statements, except as required by law. Contacts: IR@microbotmedical.comMedia@microbotmedical.com

Continue Reading →
1 2 3 … 142